529 related articles for article (PubMed ID: 37504358)
1. Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.
Teng YS; Yu S
Curr Oncol; 2023 Jul; 30(7):6805-6819. PubMed ID: 37504358
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Chen CH; Yu HS; Yu S
Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
[TBL] [Abstract][Full Text] [Related]
3. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
4. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous manifestations associated with immune checkpoint inhibitors.
Watanabe T; Yamaguchi Y
Front Immunol; 2023; 14():1071983. PubMed ID: 36891313
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
7. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Jo W; Won T; Daoud A; Čiháková D
Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
[TBL] [Abstract][Full Text] [Related]
9. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
10. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
11. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies.
Seervai RNH; Sinha A; Kulkarni RP
Clin Exp Dermatol; 2022 Nov; 47(11):1928-1942. PubMed ID: 35844072
[TBL] [Abstract][Full Text] [Related]
13. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
15. [Immune checkpoint inhibitors induced pituitary immune-related adverse events: diagnosis and management].
Gu YC; Xie C; Cao BS
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1344-1351. PubMed ID: 36575785
[TBL] [Abstract][Full Text] [Related]
16. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
Gault A; Anderson AE; Plummer R; Stewart C; Pratt AG; Rajan N
Br J Dermatol; 2021 Aug; 185(2):263-271. PubMed ID: 33393076
[TBL] [Abstract][Full Text] [Related]
18. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]